BACKGROUND. In the prostate, androgens play a crucial role in normal and cancerous growth; hence the androgenic pathway has become a target of therapeutic intervention. Dutasteride is a 5 alpha-reductase (5AR) inhibitor currently being evaluated both for chemoprevention and treatment of prostate cancer. Dutasteride inhibits both 5AR I and II enzymes, effectively blocking conversion of testosterone to dihydrotestosterone (DHT) in the prostate. This greatly reduces the amount of the active ligand DHT available for binding to the androgen receptor (AR) and stimulating proliferation, making this a good candidate for chemoprevention of prostate cancer. In this study, we sought to determine how dutasteride is functioning at the molecular level, using a prostate cancer xenograft model. METHODS. Androgen-responsive LuCaP 35 xenograft tumors were grown in Balb/c mice. Subcutaneously implanted time-release pellets were used for drug delivery. Microarray analysis was performed using the Affymetrix HG-U133Av2 platform to examine changes in gene expression in tumors following dutasteride treatment. RESULTS. Dutasteride significantly reduced tumor growth in LuCaP 35 xenografts by affecting genes involved in apoptotic, cytoskeletal remodeling, and cell cycle pathways among others. Notably, genes in the Rho GTPase signaling pathway, shown to be important in androgen-deprivation conditions, were significantly up-regulated. CONCLUSION. We have identified multiple pathways outside of the androgenic pathway in prostate cancer xenografts affected by treatment with dutasteride. These findings provide insights into the function of dutasteride within the tumor microenvironment, potentially allowing for development of agents that can be used in combination with this drug to further enhance its effectiveness.
INTRODUCTION
Prostate cancer continues to be a leading cause of cancer death in males worldwide. In the prostate, androgens play a crucial role in both normal and cancerous growth; hence, the androgenic pathway has become a target of therapeutic intervention. Testosterone is converted by 5 alpha-reductase (5AR) isoenzymes to the more potent ligand dihydrotestosterone (DHT), which binds to the androgen receptor (AR) thus promoting proliferation and survival of target tissues, such as the prostate. Dutasteride is a novel dual 5AR inhibitor (SRD5I) that is currently being investigated as a potential chemopreventive agent for prostate cancer in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial [1] . By blocking the conversion of testosterone to DHT, dutasteride reduces the amount of the more active ligand, resulting in reduced proliferative activity of the cells within the prostate. The REDUCE trial is designed to determine if dutasteride administered at 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. Another clinical trial, the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM), is evaluating whether dutasteride extends time to prostate cancer progression [2] . These trials underscore the need for a better understanding of how dutasteride is working at the molecular level.
Dutasteride has been shown to kill prostate cancer cells both in vitro [3, 4] and in vivo [5, 6] . In previous studies we determined changes in gene expression profiles in a number of prostate cancer cell lines following dutasteride treatment in vitro [4, 7] . In the current study we have extended these findings to a mouse model, using microarray analysis of prostate cancer xenografts, in order to delineate effects of the tumor-host microenvironment.
MATERIALS AND METHODS

LuCaPXenografts and DrugTreatment
The LuCaP 35 androgen-dependent prostate cancer xenograft was obtained from Dr. Robert Vessella (University of WA, Seattle) and was maintained by passage in athymic Balb/c mice (Harlan Labs, Indianapolis, IN). Animals were housed in the Mayo Clinic pathogen-free rodent facility, and all procedures performed were approved by the Mayo Clinic Institutional Animal Care and Use Committee. For this study, newly inoculated tumors were allowed to proliferate for 6 weeks, at which time dutasteride or placebo pellets formulated by Innovative Research (Innovative Research of America, Sarasota, FL) were implanted subcutaneously. The dutasteride pellets were timerelease pellets designed to deliver 1 mg/kg/day of drug. Mice were bled pre-implantation for baseline serum values of both PSA and testosterone and initial tumor measurements noted. After 8 days of treatment, mice were bled, sacrificed, and tumors harvested into liquid nitrogen. Tumor tissue was stored at À808C.
SerumTesting
Serum samples were obtained by cheek bleeds of mice using Microtainer tubes (BD, San Jose, CA). Serum testosterone levels were measured by coated well ELISA (DSL, Webster, TX) both before and after pellet implantation to verify drug delivery. Serum PSA levels were determined by ELISA (DSL) pre-and post-implantation. All samples were run in duplicate.
RNA Preparation and Microarray
RNA was isolated from xenograft tumor tissue using Trizol (Invitrogen, Carlsbad, CA) followed by purification on RNeasy columns (Qiagen, Germantown, MD) then checked for integrity by Agilent testing (Affymetrix, Santa Clara, CA). Subsequently, cDNA was generated and hybridized to Affymetrix HG-U133Av2 DNA microarrays following manufacturer's protocol in the Mayo Advanced Genomics Technology Microarray Shared Resource core facility.
Statistical Analysis
Microarray results were analyzed using the software R and R-packages fastlo and rma. The non-background corrected intensity data from the Affymetrix CEL files were normalized using fastlo [8] a faster model-based intensity-dependent normalization method that produces results essentially the same as those from cyclic loess [9] . Subsequently, the probe-level data for each probeset was summarized using Tukey's median polish [10] implemented in the rma package. The summarized probeset values represent an overall measure of expression for the corresponding gene. To assess differential expression between the dutasteride and placebo groups the statistical t-test assuming unequal variances was utilized. A false discovery rate [11] , which is the expected proportion of false discoveries amongst the rejected hypotheses, was calculated for each probeset. A fold-change ratio was calculated for each probeset based on the average expression for the placebo group divided by the average expression for the dutasteride group. Probesets that were deemed significant were then sorted by the log 2-transform of this fold-change ratio. Pathway analysis was performed using MetaCore pathway analysis and data mining application GeneGo. The differentially expressed genes with P-values 0.05 (2,062 probesets) selected from the previous step were used as focus genes and the Affymetrix HG-U133Av2 gene list used as reference.
Real-Time PCR
Two-step real-time PCR was performed using cDNA prepared from RNA described above using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) on an ABI The Prostate PRISM 7700 SDS following manufacturer's instructions. Primers for SYBR green amplification were designed using the Primer3 software (http:// www-genome.wi.mit.edu/cgi-bin/primer/primer3_ www.cgi) and both forward and reverse primers were used at a final concentration of 900 nM. PCR products (120-150 bp) were run on 1.2% agarose gels to check for non-specific amplification. Relative expression levels were determined by the comparative C T method using the formula 2 ÀDDC T where C T is the threshold cycle of amplification. Samples were run in triplicate with primers to GAPDH used for normalization.
RESULTS
Xenograft Response to DutasterideTreatment
LuCaP 35 androgen-dependent prostate xenograft tumors were developed along with their androgenindependent variant LuCaP 35V as a model for studying progression to androgen independence. The LuCaP 35 tumors express a wild-type AR, produce PSA and respond to androgen ablation comparable to that observed in humans [12] , making this an ideal model for studying drug response. Dutasteride was delivered using time-release pellets and parameters of drug delivery were initially determined by implanting the pellets and monitoring serum testosterone levels in the mice. The dutasteride time-release pellets were designed to deliver 1 mg/kg/day of drug. As dutasteride inhibits the conversion of testosterone to DHT, the resultant elevated serum levels of testosterone were used as an indicator of successful drug delivery. We performed several trials using this method to monitor drug delivery and found that by 7-10 days serum testosterone levels were consistently elevated (data not shown). Our objective was to examine early molecular events occurring with dutasteride treatment, so we limited treatment time to that which would achieve adequate drug exposure without compromising the ability to detect early gene response. We know from previous work with PCa cells in vitro that significant changes in gene expression are occurring at this time with dutasteride treatment [4, 7] . Thegraphedvaluesrepresentthesixmicechosenfor themicroarray analysis. Measurements were performed on duplicate serum samples. B: Tumor volumes were measured before and after treatment. Tumor growth in the dutasteride group was significantly less than in the placebo group, P ¼ 0.0426. C: Serum PSA levels of the xenograft-bearing mice were determined by EIA pre-and posttreatment. There is no statistically significant difference in the change in PSA values between placebo-and dutasteride-treated mice, P ¼ 0.3031. For this study, LuCaP 35 tumor tissue was inoculated into athymic Balb/c mice and allowed to proliferate for 6 weeks. Tumor growth rates and volumes varied so at the time of treatment mice were randomly sorted into pairs with similarly matched tumor sizes. Mice were bled pre-implantation for baseline serum values of both PSA and testosterone and initial tumor volumes were measured. Pellets were then implanted subcutaneously in the posterior dorsal flank, as pictured in Figure 1 , with half of the mice receiving placebo pellets and the other half receiving dutasteride pellets. After 8 days of treatment, mice were bled and sacrificed, and tumors were harvested and measured. At that time, mice from each group that demonstrated the best response to the dutasteride treatment, as determined by serum testosterone levels, were chosen for RNA isolation and further analysis. Figure 2A shows the testosterone levels of the mice chosen for microarray analysis.
The Prostate
The rate of tumor growth was diminished significantly in the dutasteride-treated mice when compared to the placebo group ( Fig. 2B , dutasteride mice average increase 46 AE 9% vs. placebo average increase 133 AE 35%, P-value ¼ 0.04263). Although PSA levels for the most part paralleled tumor volume, no statistically significant effect of dutasteride treatment on PSA levels was found, P ¼ 0.3031 (Fig. 2C ). This is not unexpected; it is important to note that treatment with an SRD5I like dutasteride is not the same as castration or androgen ablation and although DHT levels have been diminished, the increased testosterone levels can also continue to regulate tumor growth and androgen-regulated genes such as PSA. While tumor size and PSA levels are not decreased dramatically at this time point, testosterone levels are elevated, indicating effective drug uptake, so this appears to be a relevant time point for measuring early gene expression changes with respect to dutasteride treatment that may eventually affect tumor response.
Gene Expression Changes With DutasterideTreatment
RNA samples obtained from xenograft tumors of the three placebo-and three dutasteride-treated mice shown in Figure 2A were used to generate cDNA probes, which were hybridized to Affymetrix HG-U133Av2 microarrays. Table I is a partial list of the array data ranked by absolute value of log 2 foldchange. The entire list can be viewed at http:// www3.interscience.wiley.com. The top 100 genes affected by dutasteride treatment are presented as a Heatmap shown in Figure 3 . The top 100 were determined by selecting all probesets with an unequal-variance t-test P-value 0.05, then sorting this list of 2,062 by the absolute value of the log 2 foldchange. As with clinical cancers, LuCaP 35 tumors exhibit heterogeneous growth; after implantation, tumors grew at different rates and in order to best mimic the clinical situation we included both the fastgrowing and slow-growing tumors in this study. While we assayed tumors with starting volumes from <50 to >300 mm 3 in size, a number of consistent changes were observed with respect to gene expression between the tumors treated with dutasteride versus placebo (Table I and Fig. 3 ).
To validate the array data we used real-time PCR with primers to several genes from Table I that had significant fold-change ratios, such as TNFSF10 (TRAIL) which had higher expression levels in dutasteride-treated mice and CRISP3 which exhibited lower levels. We have demonstrated previously that genes involved in TRAIL-mediated apoptosis are induced in prostate cancer cells treated with dutasteride [4] . Moreover, there is evidence that prostate cancer patients with higher levels of CRISP3 have a smaller probability of recurrence-free outcomes [13] . Figure 4 shows real-time profiles for five of these genes (A) and
The Prostate corresponding Affymetrix data (B) confirming their changes in expression following treatment. Additionally, we examined the profiles of AR and klk3 (PSA) even though these genes were not significantly affected at the mRNA level by dutasteride treatment based on the array data, and this was confirmed by real-time PCR. In our previous work with LNCaP cells in vitro, we observed a twofold increase in AR expression and a decrease in PSA [4] . This was also observed by Biancolella et al. [14] in their work examining dutasteride's effects on genes involved in androgen metabolism. Both of these studies used relatively high levels of dutasteride (10 mM), which results in marked levels of cell death. We hypothesize that with a higher drug dose or longer treatment time, our LuCaP xenografts would exhibit similar changes.
While AR mRNA levels are not consistently altered at this time point, a number of AR coregulators, such as NCOA2, TMF1, PB1, XRCC5, and PIAS1 to name a few, were significantly affected (Table I and Fig. 4 ). It has been demonstrated that androgens can modulate AR coregulator expression, resulting in marked effects on AR activity in prostate cancer cells [15] and altered expression in these xenografts may be significant with regard to androgen regulation of genes involved in proliferation. Gene expression changes detected by array analysis were confirmed by real-time PCR for all of the genes we have chosen to examine.
Pathway Analysis
A primary goal of this study was to examine the functional pathways of the genes that were significantly affected by dutasteride treatment. The MetaCore pathways analysis tool was used to map the 2,062 probesets with P-values 0.05 to well-curated pathways database and functional classes. Table II lists the top 40 pathways sorted by a significant enrichment P-value, with 38 of these exhibiting a false discovery rate <0.25. The pathways affected by dutasteride treatment fell into categories ranging from apoptosis to lipid metabolism as illustrated in Figure 5A . The signaling pathway that was most significantly affected, cytoskeletal remodeling: regulation of actin by Rho GTPases is illustrated in Figure 5B . Of the 23 known genes in this pathway, 12 were significantly affected at the mRNA level by dutasteride treatment. This observation may be important, as it has been demonstrated previously that ligand-independent activation of the androgen receptor in prostate cancer progression can occur via Rho GTPase signaling [16] , specifically in the presence of low levels of androgens. Vav3 is a Rho GTPase guanine nucleotide exchange factor (GEF) whose expression has been shown to increase in LNCaP cells with progression to androgen independence and can enhance AR activity at sub-nanomolar concentrations of androgen [17] . This gene was significantly up-regulated in the LuCaP 35 xenografts with dutasteride treatment based on our array data and was confirmed by real-time PCR (data not shown). Genes in this pathway may offer an opportunity for therapeutic intervention, whereby inhibition in addition to androgen deprivation may result in total inactivation of androgen-directed activity in prostate cancer cells.
Another potentially important observation is that the ubiquitin ligase Skp2 and related genes are downregulated following dutasteride treatment of LuCaP 35 xenografts. Skp2 is involved in G1/S phase transition and progression through S phase in the cell cycle by degrading p27 Kip1 , a negative regulator of cell cycle progression [18] . Skp2 has been found to be overexpressed in prostate cancer; elevated expression of Skp2 correlates with a poor prognosis and has been proposed as a target for therapeutic intervention [19] . Skp2, Cul1 and related cyclin-dependent kinases CDK2 and CDK4 all demonstrate decreased levels of expression in dutasteride-treated xenografts (Table I  and Fig. 3 ), indicating this may be an additional basis for decreased proliferation in these tumors. Table III shows the comparison of significantly regulated genes between the LuCaP 35 xenografts in vivo and our previous in vitro work with the androgenresponsive prostate cancer cell line LNCaP [4, 7] following dutasteride treatment. The table lists the 92 Affymetrix probesets that have P-values of 0.05 in both the in vivo data and in vitro data that also demonstrated changes going in the same direction. By chance alone, this list would have $28 probesets out of the 22,215 probesets, so the results well exceed that threshold lending validity to these findings. Figure 6A is a Heatmap of the 92 probesets common to both analyses, while Figure 6B shows where these common genes fit into the pathway analysis data from the LuCaP 35 xenograft data. We feel this group of common genes is especially worth examining further as they represent
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The Prostate Delineating which pathways are critical for survival in prostate cells undergoing androgen deprivation will be an important outgrowth of this study.
DISCUSSION
Dutasteride is highly effective at lowering DHT levels in men with both BPH and prostate cancer, and is currently being evaluated for its efficacy in reducing both the risk of developing prostate cancer in the REDUCE trial [1] and in treating prostate cancer in the REDEEM trial [2] . In view of this, it is important to understand how dutasteride is working in prostate cancer cells at the molecular level and what changes are occurring in these cells in response to the drastic reduction in DHT achieved by treatment. Our previous work with prostate cancer cell lines in vitro identified genes and pathways involved in cell cycle regulation, apoptosis, and fatty acid metabolism, in addition to the androgenic pathway, as being affected by dutasteride treatment. In the current study we extended these findings into a mouse xenograft model and discovered new pathways, such as Rho GTPase regulation of cytoskeleton remodeling, which helped to elucidate how prostate cells are responding to this drug in the context of the tumor microenvironment. It has been demonstrated previously by molecular profiling of a related xenograft LuCaP 23.1, that different populations of cells exist in these tumors which exhibit distinct molecular profiles as they progress to androgen independence following androgen ablation [20] . Similarly, the LuCaP 35 xenografts we have used in this study exhibited different rates of growth, with some tumors growing much more rapidly than others. We initially sorted our mice into matched pairs based on initial tumor volumes and included tumors with varying growth rates in our study groups. We have demonstrated that though these tumors grow at different rates, dutasteride significantly decreased the growth rate in all of the treated tumors and can exert similar effects on heterogeneous cell populations through some common pathways, regardless of the tumor's initial molecular profile.
CONCLUSION
Reduction of DHT by inhibition of 5AR activity is a legitimate approach in the attempt to reduce the risk of prostate cancer development and also is a potentially valuable tool in disease management. However, it is known that androgen-deprivation therapy does not completely inactivate the androgen axis and that prostate tumor cells eventually progress to a castration-recurrent state. By defining how an SRD5I like dutasteride is working at the molecular level in prostate tumors it may be possible to develop better agents that can be used in combination with this drug to further enhance its effectiveness.
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